Major trial shows targeted drug improves survival in early-stage breast cancer with inherited BRCA1 or BRCA2 mutation 16 Mar 2022 The ICR strongly welcomes new findings that the targeted drug olaparib improves survival in women with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes. Find out more Show/Hide
ASCO 2021: Trial shows benefits of targeted drug against early-stage breast cancer with inherited BRCA mutation 03 Jun 2021 Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial. Find out more Show/Hide